Home > Healthcare > Drug Device Combination > Therapeutic Systems > Radiotherapy Induced Oral Mucositis Treatment Market

Radiotherapy Induced Oral Mucositis Treatment Market Trends

Report ID: GMI9225
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Radiotherapy Induced Oral Mucositis Treatment Market Trends

Increasing research activities in the field of radiotherapy-induced oral mucositis treatment by fostering innovation and the development of novel therapies is driving the market growth.

For instance, in May 2023, Soligenix, Inc. received a patent titled "Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis" from the European Patent Office. This patent adds to their existing intellectual property portfolio, which includes patents issued in the U.S., New Zealand, Japan, Australia, and Singapore, as well as numerous pending patent applications in various other jurisdictions globally. These research efforts aim to enhance understanding of mucositis pathophysiology, identify new therapeutic targets, and improve treatment efficacy and patient outcomes.
Therefore, growing research activities along with collaborations between academics, industry, and regulatory bodies contribute to the translation of research findings into clinically relevant interventions, thereby propelling market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The radiotherapy induced oral mucositis treatment market was valued at USD 2.5 billion in 2023 and is estimated to grow at 4.4% CAGR from 2024 to 2032, driven by the increasing incidence of cancer coupled with advancements in radiotherapy techniques.

The medication segment in the radiotherapy induced oral mucositis treatment industry is anticipated to reach USD 2.3 billion by end of 2032, due to its widespread adoption and effectiveness in treating various conditions.

North America radiotherapy induced oral mucositis treatment market size generated USD 864.4 million in 2023, attributed to its advanced healthcare infrastructure, significant investments in the oncology field, and a high prevalence of cancer cases.

Amgen Inc., Aurora BioScience, Colgate-Palmolive Company, Galera Therapeutics, Enzychem Lifesciences Corporation, EpicentRx, Izun Pharmaceuticals, MuReva Phototherapy Inc., Solasia Pharma K.K. and Soligenix Inc.